Literature DB >> 10720329

Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation.

S A Castner1, G V Williams, P S Goldman-Rakic.   

Abstract

Chronic blockade of dopamine D2 receptors, a common mechanism of action for antipsychotic drugs, down-regulates D1 receptors in the prefrontal cortex and, as shown here, produces severe impairments in working memory. These deficits were reversed in monkeys by short-term coadministration of a D1 agonist, ABT 431, and this improvement was sustained for more than a year after cessation of D1 treatment. These findings indicate that pharmacological modulation of the D1 signaling pathway can produce long-lasting changes in functional circuits underlying working memory. Resetting this pathway by brief exposure to the agonist may provide a valuable strategy for therapeutic intervention in schizophrenia and other dopamine dysfunctional states.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10720329     DOI: 10.1126/science.287.5460.2020

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  96 in total

Review 1.  Update on childhood-onset schizophrenia.

Authors:  J L Rapoport; G Inoff-Germain
Journal:  Curr Psychiatry Rep       Date:  2000-10       Impact factor: 5.285

2.  The physiological role of 5-HT2A receptors in working memory.

Authors:  Graham V Williams; Srinivas G Rao; Patricia S Goldman-Rakic
Journal:  J Neurosci       Date:  2002-04-01       Impact factor: 6.167

3.  Prefrontal dopamine D1 receptors and working memory in schizophrenia.

Authors:  Anissa Abi-Dargham; Osama Mawlawi; Ilise Lombardo; Roberto Gil; Diana Martinez; Yiyun Huang; Dah-Ren Hwang; John Keilp; Lisa Kochan; Ronald Van Heertum; Jack M Gorman; Marc Laruelle
Journal:  J Neurosci       Date:  2002-05-01       Impact factor: 6.167

4.  Regulation of dopamine D1 receptor function by physical interaction with the NMDA receptors.

Authors:  Lin Pei; Frank J S Lee; Anna Moszczynska; Brian Vukusic; Fang Liu
Journal:  J Neurosci       Date:  2004-02-04       Impact factor: 6.167

Review 5.  The treatment of cognitive impairment in schizophrenia.

Authors:  Donald C Goff; Michele Hill; Deanna Barch
Journal:  Pharmacol Biochem Behav       Date:  2010-11-27       Impact factor: 3.533

6.  Probing cortical dopamine function in schizophrenia: what can D1 receptors tell us?

Authors:  Anissa Abi-Dargham
Journal:  World Psychiatry       Date:  2003-10       Impact factor: 49.548

7.  A role for prefrontal calcium-sensitive protein phosphatase and kinase activities in working memory.

Authors:  Jason D Runyan; Anthony N Moore; Pramod K Dash
Journal:  Learn Mem       Date:  2005 Mar-Apr       Impact factor: 2.460

Review 8.  Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia.

Authors:  Jiri Horacek; Vera Bubenikova-Valesova; Milan Kopecek; Tomas Palenicek; Colleen Dockery; Pavel Mohr; Cyril Höschl
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

9.  Characterization of PF-6142, a Novel, Non-Catecholamine Dopamine Receptor D1 Agonist, in Murine and Nonhuman Primate Models of Dopaminergic Activation.

Authors:  Rouba Kozak; Tamás Kiss; Keith Dlugolenski; David E Johnson; Roxanne R Gorczyca; Kyle Kuszpit; Brian D Harvey; Polina Stolyar; Stacey J Sukoff Rizzo; William E Hoffmann; Dmitri Volfson; Mihaly Hajós; Jennifer E Davoren; Amanda L Abbott; Graham V Williams; Stacy A Castner; David L Gray
Journal:  Front Pharmacol       Date:  2020-07-07       Impact factor: 5.810

Review 10.  Psychopharmacological approaches to modulating attention in the five-choice serial reaction time task: implications for schizophrenia.

Authors:  Y Chudasama; T W Robbins
Journal:  Psychopharmacology (Berl)       Date:  2004-04-08       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.